Embedded Files
Day 1
09:00–09:15 | Institutional Opening
09:00–09:15 | Institutional Opening
Welcome and introduction by the organizing committee. Event objectives.
09:15–10:45 | Session 1: Genomics and Epigenetics in CLL
09:15–10:45 | Session 1: Genomics and Epigenetics in CLL
“Evolutionary multiclonality in CLL” – 25 min
“Tumor metabolism: new therapeutic windows” – 15 min
“Current tools for genetic risk assessment in CLL” – 15 min
“Integration of genomics, epigenetics, and proteomics in CLL stratification: toward a more precise biological classification” – 15 min
10:45–11:15 | Coffee Break
10:45–11:15 | Coffee Break
11:15–12:15 | Session 2: Tumor Microenvironment and Targeted Therapies
11:15–12:15 | Session 2: Tumor Microenvironment and Targeted Therapies
“MBL” – 15 min
“Immune dysfunction in CLL: phenotypic and functional characteristics of the immune system” – 15 min
“The tumor microenvironment in CLL: novel therapeutic targets, translational advances, and perspectives from tumor biology” – 15 min
Questions – 15 min
12:15–13:30 | Lunch Symposium A
12:15–13:30 | Lunch Symposium A
Symposium 60 min (40 min talk + 20 min Q&A)
13:30–14:00 | Coffee Break
13:30–14:00 | Coffee Break
14:00–15:00 | Session 3: Debate
14:00–15:00 | Session 3: Debate
What is currently the best fixed-duration frontline therapy?
A + V
V + I
O + V
15:00–15:45 | Session 4: Frontline Update – Continuous Therapies
15:00–15:45 | Session 4: Frontline Update – Continuous Therapies
BTKi monotherapy: IBRU / ACALA / ZANU – Continuous Therapy – 20 min
Triplets – 15 min
Discussion – 10 min
16:00–17:00 | Symposium B
16:00–17:00 | Symposium B
Symposium 60 min (40 min talk + 20 min Q&A)
Day 2
08:00 a.m. Coffee meeting (small groups)
08:00 a.m. Coffee meeting (small groups)
09:00–09:30 | Session 4: MRD / Relapsed CLL
09:00–09:30 | Session 4: MRD / Relapsed CLL
“Monitoring minimal residual disease (MRD): technical standards and clinical relevance” – 15 min
“Relapsed CLL – treatment sequencing” – 15 min
(Intra-session Q&A: 12-min talks + 3-min questions?)
09:30–10:15 | Session 5: Management of Double-Refractory Disease
09:30–10:15 | Session 5: Management of Double-Refractory Disease
“Resistance to BTK and BCL2 inhibitors in CLL: molecular mechanisms, definitions, and emerging therapies (BTK degraders)” – 15 min
“Advances in immunotherapy for CLL: CAR-T, bispecific antibodies, and tumor vaccines” – 15 min
10:15–10:45 | Coffee Break
10:15–10:45 | Coffee Break
10:45–12:00 | Oral Presentations
10:45–12:00 | Oral Presentations
3 basic science + 3 clinical presentations
12:00–13:00 | Lunch Symposium A
12:00–13:00 | Lunch Symposium A
13:15–13:45 | Session 6: Hairy Cell Leukemia
13:15–13:45 | Session 6: Hairy Cell Leukemia
“Future perspectives in hairy cell leukemia: toward new therapeutic targets” – 15 min talk + discussion
“Richter transformation” – 15 min
14:00–14:45 | Session 7: Immunization and Infection Prevention
14:00–14:45 | Session 7: Immunization and Infection Prevention
Use of immunoglobulins in CLL – which and when
“Infectious prevention in CLL: supportive strategies and practical recommendations”
“Regional immunization protocols in CLL: lessons from the pandemic and beyond”
Autoimmunity – immune cytopenias in CLL: AIHA / ITP / pure red cell aplasia
15:00–16:00 | Symposium B (Coffee)
15:00–16:00 | Symposium B (Coffee)
16:00–16:45 | Session 8: Patient Experience and Clinical Research
16:00–16:45 | Session 8: Patient Experience and Clinical Research
“What do CLL patients have to say? Global perspectives and available resources”
“Active clinical research in LATAM”
17:00–18:30 | Poster Session (1.5 h)
17:00–18:30 | Poster Session (1.5 h)
Categories: genomics/epigenetics, microenvironment, clinical, real-world LATAM, MRD
19:00 | Closing Ceremony
19:00 | Closing Ceremony
Tributes – Awards – Conclusions and Future Directions in Latin America
Page updated
Google Sites
Report abuse